Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.

Autor:	Murrough JW; Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Soleimani L; Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., DeWilde KE; Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Collins KA; Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Lapidus KA; Departments of Psychiatry and Neurobiology,Stony Brook University,Stony Brook,NY,USA., Iacoviello BM; Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Lener M; Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Kautz M; Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Kim J; Deparment of Psychology,UCLA,Los Angeles,CA,USA., Stern JB; Department of Psychology,Drexel University,Philadelphia,PA,USA., Price RB; Department of Psychiatry,University of Pittsburgh School of Medicine,Pittsburgh,PA,USA., Perez AM; Department of Anesthesiology,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Brallier JW; Department of Anesthesiology,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Rodriguez GJ; Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Goodman WK; Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Iosifescu DV; Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA., Charney DS; Mood and Anxiety Disorders Program,Department of Psychiatry,Icahn School of Medicine at Mount Sinai,New York,NY,USA.
Jazyk:	angličtina
Zdroj:	Psychological medicine [Psychol Med] 2015 Dec; Vol. 45 (16), pp. 3571-80. Date of Electronic Publication: 2015 Aug 12.
DOI:	10.1017/S0033291715001506
Abstrakt:	Background: Suicide is a devastating public health problem and very few biological treatments have been found to be effective for quickly reducing the intensity of suicidal ideation (SI). We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression. Method: We conducted a randomized, controlled trial of ketamine in patients with mood and anxiety spectrum disorders who presented with clinically significant SI (n = 24). Patients received a single infusion of ketamine or midazolam (as an active placebo) in addition to standard of care. SI measured using the Beck Scale for Suicidal Ideation (BSI) 24 h post-treatment represented the primary outcome. Secondary outcomes included the Montgomery-Asberg Depression Rating Scale--Suicidal Ideation (MADRS-SI) score at 24 h and additional measures beyond the 24-h time-point. Results: The intervention was well tolerated and no dropouts occurred during the primary 7-day assessment period. BSI score was not different between the treatment groups at 24 h (p = 0.32); however, a significant difference emerged at 48 h (p = 0.047). MADRS-SI score was lower in the ketamine group compared to midazolam group at 24 h (p = 0.05). The treatment effect was no longer significant at the end of the 7-day assessment period. Conclusions: The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior. Larger, well-powered studies are warranted.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu